No Data
No Data
No Data
KBio Announces FDA Clearance of IND Application for EV68-228-N for the Treatment of Acute Flaccid Myelitis and the First Patient Dosed in the Phase 1 Study
• The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for EV68-228-N, a human monoclonal IgG1 against the capsid of enterovirus D68 (EV-D68) designed as an
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial
Dynavax Technologies (DVAX) said late Thursday the first participant has been dosed in its phase 1/2 study of its vaccine candidate Z-1018 to prevent shingles, a disease caused by the varicella-zoster
Elanco Shares Fall 20%+ on Warning-Label Concerns for Animal Drug Zenrelia
Shares of Elanco Animal Health fell after the company said a warning that will be put on its dermatitis treatment for dogs could slow down adoption of the product.
Arthrosi Announces First Patient Dosed in Pivotal Phase 3 REDUCE 2 Trial of Lead Compound AR882
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation...
Express News | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd)
Express News | Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA
No Data